secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064473
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q1 revenue $139M, reaffirms FY2025 guidance; UX111 PDUFA Aug 18, 2025
--------------------------------------------------------------------------------

- Q1 total revenue $139M (+28% YoY); net loss $151M ($1.57/share) vs $171M ($2.03) in Q1 2024.
- Crysvita revenue $103M (+25% YoY); Dojolvi $17M; Evkeeza $11M; Mepsevii $8.4M.
- Reaffirmed FY2025 guidance: total revenue $640-670M, Crysvita $460-480M, Dojolvi $90-100M.
- UX111 BLA for Sanfilippo granted Priority Review; PDUFA date Aug 18, 2025; potential H2 launch.
- DTX401 BLA for GSDIa expected mid-2025; GTX-102 Ph3 enrollment completion H2 2025; cash $563M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/0000950170-25-064473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer